Financials data is unavailable for this security.
View more
Year on year ZhuZhou QianJin Pharmaceutical Co Ltd had revenues fall -5.66% from 4.03bn to 3.80bn, though the company grew net income 5.53% from 303.63m to 320.41m.
| Gross margin | 45.06% |
|---|---|
| Net profit margin | 9.88% |
| Operating margin | 11.25% |
| Return on assets | 8.25% |
|---|---|
| Return on equity | 12.43% |
| Return on investment | 15.12% |
More ▼
Cash flow in CNYView more
In 2023, ZhuZhou QianJin Pharmaceutical Co Ltd increased its cash reserves by 75.00%, or 826.40m. Cash Flow from Investing totalled 585.29m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 443.12m in cash from operations while cash used for financing totalled 202.00m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 5.69 |
|---|---|
| Tangible book value per share | 5.12 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.56 |
|---|---|
| Quick ratio | 2.18 |
| Total debt/total equity | 0.1255 |
|---|---|
| Total debt/total capital | 0.09 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 7.94%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 5.56% |
|---|---|
| Div growth rate (5 year) | -2.64% |
| Payout ratio (TTM) | 51.56% |
| EPS growth(5 years) | 4.64 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -5.81 |
More ▼
